Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Elsa Miekoutima"'
Autor:
Natacha Johnson, Marie Templé, Chloe Friedrich, Lise Willems, Rudy Birsen, Marguerite Vignon, Paul Deschamps, Patricia Franchi, Johanna Mondesir, Benedicte Deau-Fischer, Elsa Miekoutima, Ismaël Boussaid, Nicolas Chapuis, Olivier Kosmider, Didier Bouscary, Jerome Tamburini, Justine Decroocq
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Externí odkaz:
https://doaj.org/article/2abb127402f94d7c938ea21ea52a9c4d
Autor:
Jeremie Zerbit, Marion Detroit, Antoine Meyer, Justine Decroocq, Benedicte Deau-Fischer, Paul Deschamps, Rudy Birsen, Johanna Mondesir, Patricia Franchi, Elsa Miekoutima, Corinne Guerin, Rui Batista, Didier Bouscary, Lise Willems, Marguerite Vignon
Publikováno v:
Viruses, Vol 14, Iss 11, p 2377 (2022)
Background: Patients with hematological malignancies are at greater risk of severe COVID-19 and have been prioritized for COVID-19 vaccination. A significant proportion of them have an impaired vaccine response, both due to the underlying disease and
Externí odkaz:
https://doaj.org/article/150d90fe231d4b148bd1bef032a18cc1
Autor:
Nabih Maslah, Norman Salomao, Louis Drevon, Emmanuelle Verger, Nicolas Partouche, Pierre Ly, Philippe Aubin, Nadia Naoui, Marie-Helene Schlageter, Cecile Bally, Elsa Miekoutima, Ramy Rahmé, Jacqueline Lehmann-Che, Lionel Ades, Pierre Fenaux, Bruno Cassinat, Stephane Giraudier
Publikováno v:
Haematologica, Vol 105, Iss 6 (2020)
Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1
Externí odkaz:
https://doaj.org/article/a3926e140b0641b5839b74cdde287c84
Autor:
Mariem Raho-Moussa, Marguerite Guiguet, Céline Michaud, Patricia Honoré, Christia Palacios, François Boué, Mohammed Azghay, Imad Kansau, Véronique Chambrin, Tania Kandel, Marion Favier, Elsa Miekoutima, Naomi Sayre, Carole Pignon, Michka Shoai, Olivier Bouchaud, Sophie Abgrall
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0213019 (2019)
Barriers to achieve sustained HIV virological suppression on antiretroviral therapy (ART) jeopardize the success of the 90:90:90 UNAIDS initiative which aims to end the HIV/AIDS epidemic. In France, where access to ART is free and universally availab
Externí odkaz:
https://doaj.org/article/1cbca1debf454fc595158e1893a12eed
Autor:
Blandine Beve, Rami S. Komrokji, Elsa Miekoutima, Jacqueline Lehmann-Che, Antoine F. Carpentier, Céline Berthon, Isabelle Madelaine, Thomas Cluzeau, Aspasia Stamatoullas, Ramy Rahmé, Anouk Walter-Petrich, Sylvie Chevret, Bruno Quesnel, Michael Loschi, Emmanuel Raffoux, David A. Sallman, Lise Willems, Habiba Attalah, Fatiha Chermat, Lionel Ades, Marie Sebert, Pierre Peterlin, Stefania Cuzzubbo, Odile Beyne Rauzy, Christian Recher, Pierre Fenaux
Publikováno v:
Journal of Clinical Oncology. 39:1575-1583
PURPOSE TP53-mutated ( TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA) alone, short re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eff360bf29a98f01724980dd9fa95091
https://doi.org/10.1200/jco.20.02342
https://doi.org/10.1200/jco.20.02342
Autor:
Aliénor Xhaard, Elsa Miekoutima, France Pirenne, Anne François, Pierre Tiberghien, Marie Sebert, Lionel Adès, Pierre Fenaux, Anne‐Claire Leprêtre
Publikováno v:
Vox sanguinisREFERENCES. 117(5)
Most myelodysplastic syndromes (MDS) patients become red blood cell (RBC) transfusion-dependent. Transfusing MDS patients with prophylactically RH-KEL1 antigen-matched (PAM) RBC units is recommended to avoid RBC allo-immunization. D+C-E-c+e+, D+C-E+c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::436da54998e33134f2d0db9f63877d19
https://pubmed.ncbi.nlm.nih.gov/34985763
https://pubmed.ncbi.nlm.nih.gov/34985763
Autor:
Jacqueline Lehmann-Che, Louis Drevon, Philippe Aubin, Elsa Miekoutima, Marie-Hélène Schlageter, Nicolas Partouche, Cecile Bally, Pierre Fenaux, Nabih Maslah, Lionel Adès, Nadia Naoui, Stéphane Giraudier, Ramy Rahmé, Norman Salomao, Bruno Cassinat, Pierre Ly, Emmanuelle Verger
Publikováno v:
Haematologica. 105:1539-1551
Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd1420f8e7b130a786c40b4ef9870154
https://doi.org/10.3324/haematol.2019.218453
https://doi.org/10.3324/haematol.2019.218453
Autor:
Thomas, Cluzeau, Marie, Sebert, Ramy, Rahmé, Stefania, Cuzzubbo, Jacqueline, Lehmann-Che, Isabelle, Madelaine, Pierre, Peterlin, Blandine, Bève, Habiba, Attalah, Fatiha, Chermat, Elsa, Miekoutima, Odile Beyne, Rauzy, Christian, Recher, Aspasia, Stamatoullas, Lise, Willems, Emmanuel, Raffoux, Céline, Berthon, Bruno, Quesnel, Michael, Loschi, Antoine F, Carpentier, David A, Sallman, Rami, Komrokji, Anouk, Walter-Petrich, Sylvie, Chevret, Lionel, Ades, Pierre, Fenaux
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(14)
This phase II study assessed the safety and efficacy of eprenetapopt in combination with AZA in untreated high or very high International Prognostic Scoring System-RFifty-twoIn this very high-risk population of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e5d85532a1474b94a2cca06bf76787f6
https://pubmed.ncbi.nlm.nih.gov/33797953
https://pubmed.ncbi.nlm.nih.gov/33797953
Autor:
Tania Kandel, Imad Kansau, Carole Pignon, Patricia Honoré, François Boué, Céline Michaud, Marion Favier, Sophie Abgrall, Mariem Raho-Moussa, Olivier Bouchaud, Naomi L. Sayre, Véronique Chambrin, Elsa Miekoutima, Marguerite Guiguet, Christia Palacios, Michka Shoai, Mohammed Azghay
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0213019 (2019)
PLoS ONE
PLoS ONE, Public Library of Science, 2019, 14 (3), pp.e0213019. ⟨10.1371/journal.pone.0213019⟩
PLoS ONE
PLoS ONE, Public Library of Science, 2019, 14 (3), pp.e0213019. ⟨10.1371/journal.pone.0213019⟩
International audience; Barriers to achieve sustained HIV virological suppression on antiretroviral therapy (ART) jeopardize the success of the 90:90:90 UNAIDS initiative which aims to end the HIV/AIDS epidemic. In France, where access to ART is free
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::debfdb6903ac29d65d7cfed601fc8239
https://doaj.org/article/1cbca1debf454fc595158e1893a12eed
https://doaj.org/article/1cbca1debf454fc595158e1893a12eed
Autor:
Habiba Attalah, Thomas Cluzeau, Sylvie Chevret, Antoine F. Carpentier, Jacqueline Lehmann che, Anouk Walter-Petrich, Aspasia Stamatoullas, Fatiha Chermat, David A. Sallman, Lionel Ades, Marie Sebert, Emmanuel Raffoux, Odile Beyne-Rauzy, Céline Berthon, Blandine Beve, Stefania Cuzzubbo, Elsa Miekoutima, Bruno Quesnel, Pierre Peterlin, Ramy Rahmé, Pierre Fenaux, Lise Willems, Christian Recher
Publikováno v:
Blood. 134:677-677
Introduction : TP53 mutated (TP53m) MDS and AML have very poor outcome irrespective of the treatment received, including 40% responses (20% CR) with azacitidine (AZA) with short response duration and a median overall survival (OS) of about 8 months (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21b8d0e9b9805c7287ebc90f1c30c271
https://doi.org/10.1182/blood-2019-125579
https://doi.org/10.1182/blood-2019-125579